Y-mAbs Therapeutics, Inc.
YMABDelisted Sep 16, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001722964
Y-mAbs Therapeutics, Inc. was delisted on Sep 16, 2025; its insiders filed their last Form 4 on Sep 19, 2025; 97 institutions reported holding it in 13F filings for Q2 2025, worth $125.9M in total; no superinvestor held it.
13F holders, Q2 2025
Institutional positions in Y-mAbs Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
YMAB is no longer listed, so this page shows Q2 2025. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 97
- −6 vs. Q1 2025
- Shares held
- 27.9M
- −901.5K (−3.1%) vs. Q1 2025
- Total value
- $125.9M
- −$1.76M (−1.4%) vs. Q1 2025
- New holders
- 13
- 29 more added
- Sold out
- 19
- 36 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting YMAB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 2 | $78.3K |
| Q2 2025 | 97 | $125.9M |
| Q1 2025 | 103 | $127.6M |
| Q4 2024 | 113 | $225.5M |
| Q3 2024 | 105 | $338.5M |
| Q2 2024 | 96 | $294.2M |
| Q1 2024 | 96 | $374.0M |
| Q4 2023 | 94 | $138.0M |
| Q3 2023 | 99 | $107.3M |
| Q2 2023 | 95 | $132.4M |
| Q1 2023 | 86 | $95.4M |
| Q4 2022 | 91 | $94.2M |
| Q3 2022 | 100 | $339.7M |
| Q2 2022 | 91 | $374.7M |
| Q1 2022 | 88 | $300.6M |
| Q4 2021 | 97 | $417.1M |
| Q3 2021 | 97 | $749.0M |
| Q2 2021 | 100 | $886.9M |
| Q1 2021 | 117 | $804.8M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Y-mAbs Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Virtus Investment Advisers, Inc. | 0 | $0 | 0.00% | −36,751−100.0% | Sold out |
| Exchange Traded Concepts, LLC | 0 | $0 | 0.00% | −26,762−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | −26,004−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −22,434−100.0% | Sold out |
| Corebridge Financial, Inc. | 0 | $0 | 0.00% | −18,305−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −14,382−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −14,141−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −13,284−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −12,654−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −12,432−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −11,084−100.0% | Sold out |
| ProShare Advisors LLC | 0 | $0 | 0.00% | −10,109−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −4,812−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −437−100.0% | Sold out |
| South State Corp. | 0 | $0 | 0.00% | −68−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −46−100.0% | Sold out |